secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001437749-23-014595
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Q1 net loss $4.1M; runway extended via $10.8M offering; EU patent granted
--------------------------------------------------------------------------------

- Net loss $4.1M ($4.76/sh) vs $8.1M in Q1 2022; operating loss narrowed to $4.2M from $8.3M.
- Cash $4.2M as of Mar 31; April public offering raised $10.8M net, funding through Q1 2024.
- R&D expense fell 74% to $1.4M; G&A down 23% to $2.3M; average monthly cash burn cut 58% YoY.
- European Patent Office granted SERCA2a activator patent coverage through July 2038.
- Regained Nasdaq minimum bid price compliance; publication on istaroxime cardiogenic shock dose-response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/0001437749-23-014595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/wint20230412_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-014595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer